We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals
ENTA

98 hedge funds and large institutions have $419M invested in Enanta Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 46 increasing their positions, 23 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

189% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 9

100% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 23

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

24% more capital invested

Capital invested by funds: $339M → $419M (+$80M)

21% more funds holding

Funds holding: 81 → 98 (+17)

15% more call options, than puts

Call options by funds: $1.35M | Put options by funds: $1.17M

Holders
98
Holders Change
+17
Holders Change %
+20.99%
% of All Funds
2.82%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.11%
New
26
Increased
46
Reduced
23
Closed
9
Calls
$1.35M
Puts
$1.17M
Net Calls
+$177K
Net Calls Change
-$223K

Top Buyers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
+$11.1M
2
EAM
Eagle Asset Management
Florida
+$10.4M
3
GT
Glenmede Trust
Pennsylvania
+$8.55M
4
BFA
BlackRock Fund Advisors
California
+$5.8M
5
SAM
Senzar Asset Management
New York
+$4.35M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$17.7M
2
HAMF
Hatteras Alternative Mutual Funds
North Carolina
-$2.36M
3
ICRM
Insight Capital Research & Management
California
-$1.85M
4
Bank of New York Mellon
Bank of New York Mellon
New York
-$1.22M
5
GPCM
Granite Point Capital Management
Massachusetts
-$1.14M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$2.44M -$1.22M -32,020 -36%
Northern Trust
27
Northern Trust
Illinois
$2.43M +$199K +5,204 +10%
AAM
28
Aureus Asset Management
Massachusetts
$2.39M +$2.12M +55,530 New
Renaissance Technologies
29
Renaissance Technologies
New York
$2.35M +$2.08M +54,600 New
AI
30
Analytic Investors
California
$2.35M +$1.42M +37,327 +217%
GTC
31
Ghost Tree Capital
New York
$2.15M +$572K +15,000 +43%
Allianz Asset Management
32
Allianz Asset Management
Germany
$2.01M -$158K -4,150 -8%
ACM
33
Apex Capital Management
Ohio
$1.94M +$242K +6,338 +16%
Geode Capital Management
34
Geode Capital Management
Massachusetts
$1.83M +$475K +12,456 +42%
BA
35
BlackRock Advisors
Delaware
$1.81M +$1.53M +40,051 +2,051%
RFC
36
Russell Frank Company
Washington
$1.77M +$169K +4,427 +10%
Arrowstreet Capital
37
Arrowstreet Capital
Massachusetts
$1.77M -$714K -18,710 -31%
DILH
38
Dai-ichi Life Holdings
Japan
$1.47M -$26.6K -697 -2%
Ameriprise
39
Ameriprise
Minnesota
$1.39M +$72.3K +1,895 +6%
Thrivent Financial for Lutherans
40
Thrivent Financial for Lutherans
Minnesota
$1.32M +$1.17M +30,731 New
BIM
41
BlackRock Investment Management
Delaware
$1.29M +$747K +19,588 +190%
Deutsche Bank
42
Deutsche Bank
Germany
$1.23M +$369K +9,661 +51%
Wells Fargo
43
Wells Fargo
California
$1.15M -$1.04M -27,248 -51%
PI
44
Putnam Investments
Massachusetts
$1.12M +$1.22K +32 +0.1%
GPCM
45
Granite Point Capital Management
Massachusetts
$1.08M -$1.14M -30,000 -55%
AQR Capital Management
46
AQR Capital Management
Connecticut
$900K +$797K +20,900 New
RFC
47
Regions Financial Corp
Alabama
$841K +$745K +19,535 New
California State Teachers Retirement System (CalSTRS)
48
California State Teachers Retirement System (CalSTRS)
California
$812K +$469K +12,300 +188%
CS
49
Credit Suisse
Switzerland
$802K +$305K +8,007 +76%
Charles Schwab
50
Charles Schwab
California
$761K +$376K +9,852 +126%
1
2
3 4 5

ENTA Hedge Fund Activity: Q2 2014 in Review

98 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q2 2014, worth a combined $419M — up 24% from $339M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new ENTA positions and 9 closed out — a net gain of 17 holders — while 46 added to existing stakes and 23 trimmed.

The largest buyer was Consonance Capital Management, adding an estimated $11.1M. The largest seller was Fidelity Investments, cutting an estimated $17.7M.

  • 98 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q2 2014, up from 81 in Q1 2014.
  • Funds reported $419M of Enanta Pharmaceuticals stock for Q2 2014, up 24% quarter-over-quarter.
  • 26 funds opened new Enanta Pharmaceuticals positions in Q2 2014 and 9 closed out, a net change of +17 holders.
  • The largest Enanta Pharmaceuticals buyer in Q2 2014 was Consonance Capital Management, an estimated $11.1M added.
  • The largest Enanta Pharmaceuticals seller in Q2 2014 was Fidelity Investments, an estimated $17.7M sold.

Based on aggregated 13F filings for Q2 2014.